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Purpose:  To  investigate  the  electroclinical  features  and  the  outcome  of  patients  with  typical
absences starting  before  the  3  years  of  life.
Methods:  We  reviewed  the  clinical  data  of  patients  with  absences  started  before  3  years
observed over  a  15-year  period.  Mutation  analysis  of  SLC2A1  (GLUT-1)  gene  was  performed
when possible.  Their  clinical  features  were  compared  with  those  of  subjects  with  a  diagnosis
of childhood  absence  epilepsy  (CAE).
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Results:  Among  33  children  with  absence  epilepsy  starting  before  3  years  of  life,  there  were  20
boys and  13  girls.  Mean  seizure  onset  was  at  28.0  ±  8.3  (range:  8—36)  months  of  life.  Two  children
displayed  borderline  intellectual  functioning  at  long-term  follow-up.  Twenty-eight  (85%)  patients
showed excellent  response  to  therapy.  Three  subjects  evolved  into  a  different  form  of  idiopathic
generalized  epilepsy  (IGE).  No  SLC2A1  mutation  was  identiﬁed  in  20  (60.6%)  patients  tested.
The main  clinical  features  of  patients  with  early-onset  absences  did  not  differ  from  those  of  CAE
except for  increased  prevalence  of  males  (p  =  0.002)  and  longer  treatment  duration  (p  =  0.001)  in
the former.
Conclusions:  Strong  similarities  in  the  electroclinical  features  and  outcome  between  children
with early-onset  absences  and  those  with  CAE  support  the  view  that  these  conditions  are  part  of
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the  ﬁrst  antiepileptic  drug  (AED)  (27  valproate,  1  lamotrig-
ine).  In  the  remaining  ﬁve  individuals,  the  add-on  of  anotherthe wide  spectrum  of  IGE.
© 2011  Elsevier  B.V.  All  right
ntroduction
hildhood  absence  epilepsy  (CAE)  is  a  well-deﬁned  syn-
rome  characterized  by  onset  of  recurrent  absences
n  otherwise  healthy,  school-aged  children  (Commission,
989;  Panayiotopoulos,  1997). Patients  typically  show  daily
bsences  (‘picnolepsy’)  consisting  of  variable  consciousness
mpairment  that  may  be  isolated  (simple  absences)  or  asso-
iated  with  motor  component,  automatisms,  and  autonomic
anifestations  (complex  absences),  with  concomitant  bilat-
ral,  regular  and  symmetrical  3—4  c/s  spike-waves  at  the
EG  (Commission,  1981,  1989;  Panayiotopoulos,  1997).
eizures  are  commonly  controlled  by  antiepileptic  drug
AED)  treatment  and  the  long-term  prognosis  is  good
Loiseau  et  al.,  2002;  Panayiotopoulos,  2005). Only  rare
ases  of  absence  epilepsy  presenting  within  the  ﬁrst  3  years
f  life  have  been  reported  thus  far  (Doose,  1994;  Chaix
t  al.,  2003;  Cavazzuti  et  al.,  1989;  Fernandez-Torre  et  al.,
005;  Shahar  et  al.,  2007;  Verrotti  et  al.,  2011;  Caraballo
t  al.,  2011). Some  authors  suggest  that  early-onset  absence
pilepsy  (EOAE)  is  a  distinct  syndrome  within  the  spectrum
f  idiopathic  generalized  epilepsies  (IGE)  showing  electro-
linical  features,  response  to  therapy,  and  prognosis,  similar
ut  not  identical  to  CAE  (Fernandez-Torre  et  al.,  2005;
hahar  et  al.,  2007). Conversely,  other  experts  consider  the
arly  appearance  of  absences  as  the  ﬁrst  manifestation  of
arious  generalized  epilepsies  with  less  favourable  outcome
ecause  of  the  frequent  concomitance  of  drug-resistance
r  neurodevelopmental  problems  (Chaix  et  al.,  2003;  Hirsch
nd  Valenti,  2010). Recently,  mutations  in  SLC2A1,  encoding
he  glucose  transporter  type  1  (GLUT1),  have  been  reported
n  up  to  12%  of  subjects  with  early-onset  absence  epilepsy
Suls  et  al.,  2009;  Mullen  et  al.,  2010).
We  evaluated  the  electroclinical  features  and  the  out-
ome  of  a  large  series  of  patients  with  absence  epilepsy
tarting  before  3  years  of  life  and  compared  them  with  those
f  subjects  with  a  diagnosis  of  CAE.
atients  and  methods
e reviewed the clinical data (including age, gender, family and
ersonal history of seizures, treatment, and outcome) of patients
ith typical daily absences observed at different Italian epilepsy
enters over a 15-year period. Inclusion criteria were: (1) onset
ithin the ﬁrst 3 years of life of (2) daily absences accompanied by
ilateral, symmetric, and synchronous regular 3—4 c/s spike-waves
ith normal background recorded at EEG or video-EEG; (3) other
ypes of seizures and normal development at the onset; and (4)
A
c
p
merved.
o evidence of brain imaging abnormalities. All the subjects were
egularly followed-up at least yearly at each center. Cognition was
valuated by Wechsler Intelligence Scale in patients older than 6
ears and by Grifﬁths scale in younger patients. We  also compared
he clinical features of the patients with those of children with CAE
age of onset: 3—8 years) (Commission ILAE, 1981) observed in the
ame period. An informed consent was signed by all participants
r their parents and approval for the study was provided by the
thics Committee at each center. Statistical analysis was obtained
sing Student unpaired t-test or Fisher’s exact test. A p-value
0.05 was considered to be signiﬁcant. Mutation analysis of SLC2A1
as performed on genomic DNA by direct sequencing in available
atients.
esults
linical  data
e  identiﬁed  33  patients  affected  by  daily  typical  absences
tarting  within  the  3  years  of  life  and  bilateral,  symmetric,
nd  synchronous  3—4  c/s  spike-waves  at  EEG  (Figs.  1  and  2).
he  demographic  and  clinical  data  of  the  patients  are
hown  in  Table  1.  There  were  20  boys  and  13  girls  (M/F
atio:  1.54/1),  with  a  mean  age  of  11.9  ±  8.4  years  (range:
.6—40.6)  at  last  follow-up.  The  mean  follow-up  duration
as  9.3  ±  8.4  years  (range:  1—38).  The  mean  age  at  seizure
nset  was  28  ±  8.0  months  (range:  8—36).  In  four  children,
bsences  appeared  within  the  ﬁrst  year  of  life  (range:  8—11
onths).  In  eight  cases  (24.2%)  there  was  at  least  one
rst-degree  relative  (father/mother  in  three,  brother/sister
n  ﬁve)  affected  by  epilepsy,  all  with  IGE.  None  of  the
atients  showed  abnormal  neurological  examination  or  asso-
iated  neurological  features,  such  as  paroxysmal  dyskinesia.
wo  children  who  displayed  borderline  intellectual  function-
ng  (IQ  =  84)  at  long-term  (9.33  and  18.16  years)  follow-up
Table  1).  One  subject  (patient  26)  experienced  few  gen-
ralized  tonic—clonic  seizures  (GTCS)  during  the  period  of
ctive  absence  epilepsy.  Other  three  subjects  developed
nother  form  of  IGE  in  the  following  years  (IGE  with  GTCS
nly  in  case  27;  juvenile  myoclonic  epilepsy  in  cases  29,
0).  Twenty-eight  (85%)  patients  became  seizure-free  withED  (4  ethosuximide,  1  levetiracetam)  was  needed  to  obtain
omplete  seizure  control.  During  the  follow-up  period,  12
atients  (60.6%)  were  off  medication  after  a  mean  treat-
ent  duration  of  6.6  ±  5.0  years  (range:  1.2—19.6).
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Table  1  Clinical  data  of  the  patients  with  earl-onset  absences.
Pt  ID Sex Age  at  last
FW  (years)
Familial
history  of
epilepsy
Seizure
onset
(months)
First  AED Response  to
therapy
(add-on  drug)
Follow-up
duration
(years)
Therapy
duration
(years)
Cognition Subsequent  IGE
(onset,  years)
SLC2A1  analysis
1 ♂ 15 — 30 VPA Yes 12.5  12.33 N — Negative
2 ♂ 4.08  — 30 VPA Yes 1.58  1.25 N — ND
3 ♀ 11.08  — 32 VPA Yes 8.41  7.91 N — ND
4 ♂ 10.33  — 11 VPA ETS 9.33  Ongoing Borderline — ND
5 ♀ 8.75  — 36 VPA Yes 5.75  5.58 N — Negative
6 ♂ 9.58  — 34 VPA Yes 6.75  3.8 N — ND
7 ♂ 9.41  — 36 VPA Yes 6.41  3.2 N — ND
8 ♀ 8.16  — 36 LTG Yes 5.16  Ongoing N — Negative
9 ♀ 1.66  — 8 VPA LEV 1 Ongoing N — Negative
10 ♂ 12.33  — 28 VPA Yes 10 3 N — Negative
11 ♀ 16.5  Mother  (IGE) 32 VPA Yes 13.91  4 N — Negative
12 ♀ 16.5  — 9 VPA Yes 15.75  7 N — Negative
13 ♀ 10.58  — 36 VPA Yes 1 Ongoing N — Negative
14 ♂ 6 — 36 VPA ETS 3 Ongoing N — Negative
15 ♂ 14.75  No 33 VPA Yes 12 Ongoing N — Negative
16 ♂ 7.08  No  24  VPA  Yes  5.08  Ongoing  N  —  Negative
17 ♀ 16.83  Brother
(IGE)
24  VPA  Yes  14.83  Ongoing  N  —  Negative
18 ♂ 5.01  Sister  (IGE) 36 VPA Yes 2.08  Ongoing  N  —  Negative
19 ♂ 4.83  No 33 VPA Yes  2.08  Ongoing  N  —  Negative
20 ♂ 3.91  No 27 VPA Yes 1.66  Ongoing  N  —  ND
21 ♀ 21 Brother
(IGE)
34 VPA Yes  18.16  Ongoing  Borderline  —  ND
22 ♂ 5.41  — 24 VPA Yes 3.41  Ongoing  N  —  ND
23 ♂ 4.16  — 29 VPA Yes  1.75  Ongoing  N  —  ND
24 ♀ 5 — 24 VPA Yes  3  Ongoing  N  —  ND
25 ♂ 11.41  — 24 VPA Yes  9.41  Ongoing  N  —  Negative
26 ♂ 32.08  — 36 VPA  Yes  29.08  Ongoing  N  —  Negative
27 ♂ 40.66  Brother
(IGE)
24 VPA  ETS  38.66  19.66  N  IGEwGTCS  (16)  ND
28 ♂ 4.91  — 24 VPA  Yes  2.91  Ongoing  N  —  ND
29 ♀ 19.16  Sister  (IGE) 32  VPA  Yes  16.5  Ongoing  N  JME  (16)  Negative
30 ♂ 19.33  Father,
mother
(IGE)
36 VPA  Yes  16.33  Ongoing  N  JME  (15)  Negative
31 ♀ 7.41  — 31 VPA Yes  4.83  3.83  N  —  ND
32 ♀ 8.41  Mother  (IGE) 9 VPA  Yes  7.66  Ongoing  N  —  Negative
33 ♂ 21.66  — 30  VPA  ETS  19.16  8.16  N  —  Negative
FW: follow-up; IGE: idiopathic generalized epilepsy; IGEwGTCS: idiopathic generalized epilepsy with generalized tonic—clonic seizures only; JME: juvenile myoclonic epilepsy; AED:
antiepileptic drug; VPA: valproate; LTG: lamotrigine; ETS: ethosuximide; LEV: levetiracetam; N: normal; ND: not done.
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Figure  1  EEG  recording  of  patient  #12  at  the  age  of  2  years  showing  of  symmetric  and  synchronous  generalized  spike-and-wave
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cischarges at  3  Hz,  lasting  9—10  s  and  accompanied  by  interrup
lter: 50  Hz.
enetic  study
LC2A  gene  analysis  was  available  in  20  (60.6%)  patients
Table  1)  but  no  mutations  were  identiﬁed.
linical  data  of  CAE  patients  and  statistical  analysis
 total  of  912  children  with  a  diagnosis  of  CAE  were
bserved  over  a  15-year  period.  The  mean  follow-up  dura-
ion  was  7.8  ±  6.6  years  (range:  1—22).  This  group  included
04  males  and  608  females  (M/F  ratio:  1:2),  with  a  mean
ge  of  7.6  ±  1.8  years.  First-degree  family  history  of  IGE
as  present  in  152  (16.6%)  subjects.  GTCS  occurred  in
03  (11.3%)  patients  during  the  period  of  active  absence
pilepsy.  Thirty-six  (3.9%)  children  showed  borderline  intel-
ectual  function.  The  ﬁrst  AED  allowed  seizure  control  in
he  large  majority  of  the  patients.  Add-on  treatment  was
equired  in  121  (13.2%)  children.  Mean  treatment  duration
as  3.8  ±  1.2  years  (range:  0.6—6).
t
3
e
e
igure  2  Sleep  EEG  recording  of  patient  #15  obtained  at  the  a
omplexes preceded  by  sleep  spindles  over  the  anterior  regions.  Lowof  word  counting.  Low  ﬁlter:  0.53  Hz;  high  ﬁlter:  35  Hz;  notch
Statistical  analysis  showed  no  difference  between  IGE
amily  history  (p  =  0.24;  Fisher’s  exact  test),  occurrence
f  GTCS  (p  =  0.  24;  Student  t-test),  intellectual  function
p  =  0.38;  Fisher’s  exact  test),  and  number  of  AEDs  (p  =  0.79)
etween  the  two  groups  except  for  an  increased  prevalence
f  males  (p  =  0.002;  Fisher’s  exact  test)  and  a longer  treat-
ent  duration  (p  =  0.001;  Student  t-test)  in  patients  with
arly-onset  absences.
iscussion
he  occurrence  of  absence  epilepsy  before  age  3  years
s  quite  infrequent,  probably  due  to  the  incomplete
aturation  of  speciﬁc  thalamocortical  pathways  neces-
ary  for  generating  3—4  c/s  spike-and-wave  complexes
Panayiotopoulos,  1997;  Loiseau  et  al.,  2002). So  far,  less
han  50  patients  with  typical  absences  starting  within  the
 years  of  life  have  been  reported  (reviewed  in  Shahar
t  al.,  2007). In  the  last  two  decades,  many  authors  (Chaix
t  al.,  2003;  Fernandez-Torre  et  al.,  2005;  Shahar  et  al.,
ge  of  30  months  and  showing  rhythmic  3-Hz  spike-and-wave
 ﬁlter:  0.53  Hz;  high  ﬁlter:  35  Hz;  notch  ﬁlter:  50  Hz.
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GA  clinical  and  genetic  study  
2007;  Verrotti  et  al.,  2011) have  attempted  to  delineate  the
electroclinical  and  the  outcome  of  these  patients.  However,
whether  this  should  be  considered  a  distinct  epileptic  syn-
drome  within  the  spectrum  of  IGE  is  still  unclear.  Indeed,
in  a  recent  study,  Caraballo  et  al.  (2011)  showed  that
absences  starting  in  the  ﬁrst  years  of  life  may  occur  in
children  with  different  epileptic  syndromes,  such  as  CAE,
benign  myoclonic  epilepsy  of  infancy,  and  eyelid  myoclonia
with  absences.  Moreover,  while  strongly  advocated  by  some
authors  (Cavazzuti  et  al.,  1989), the  view  that  these  children
show  less  favourable  seizure  control  and  impaired  cognitive
is  refused  by  other  experts  (Fernandez-Torre  et  al.,  2005;
Shahar  et  al.,  2007). These  differences  could  be  due  to  dif-
ferent  inclusion  criteria  and  study  design  within  these  series.
Alternatively,  it  can  be  more  easily  explained  by  the  evolving
concept  of  epilepsy  syndrome,  its  dynamic  characteristics
and  the  extremely  complex  pathophysiologic  mechanisms
underlying  the  epileptic  phenomena  (Striano  et  al.,  2009).
Here,  we  report  the  results  of  a  multicenter  study  includ-
ing  different  epilepsy  center  from  Italy.
This  is  the  largest  series  of  patients  with  typical  absences
starting  within  the  3  years  of  life  reported  thus  far.  Our  sam-
ple  represents  about  the  3.5%  of  all  subjects  with  absence
seizures  (‘picnolepsy’)  observed  in  the  same  period.  The
main  ﬁnding  of  our  study  is  the  evidence  that  clinical  and
EEG  features  of  patients  with  absences  starting  before  age
3  years  do  not  signiﬁcantly  differ  from  those  of  children
with  typical  CAE.  Previous  studies  suggested  that  GTCS  pre-
dict  poor  prognosis  in  CAE  (Grosso  et  al.,  2005). In  our
study,  we  found  no  correlation  between  the  clinical  out-
come  of  the  patients  and  the  presence  of  GTCS,  according  to
other  authors  (Wakamoto  et  al.,  2010). Likewise,  response
to  the  therapy  and  the  global  outcome  of  the  two  groups
of  patients  are  quite  similar.  Therefore,  we  cannot  conﬁrm
the  view  that  children  with  early-onset  absences  have  a  less
favourable  prognosis  and  more  neurodevelopmental  prob-
lems  respect  to  those  with  a  diagnosis  of  CAE.  The  reason  for
this  discrepancy  is  uncertain  but  it  could  depend  from  enroll-
ment  bias  and  different  inclusion  criteria  in  other  studies,
such  as  the  exclusion  of  other  seizure  types  and  cognitive
impairment  at  the  onset.
The  male  prevalence  in  the  group  of  patients  with  early-
onset  absences  could  result  from  a  bias  due  to  the  still
unexplained  higher  incidence  of  CAE  in  girls  (Loiseau  et
al.,  2002;  Panayiotopoulos,  2005). In  addition,  we  observed
a  longer  treatment  duration  in  the  group  of  patients  with
early-onset  absences  respect  to  those  with  CAE.  This  is  prob-
ably  due  to  the  earlier  age  at  seizure  onset  and  to  the
tendency  for  referring  clinicians  to  continue  the  therapy
until  late  childhood  in  this  group.
Some  patients  from  our  series  developed  different  forms
of  IGE  in  later  age,  conﬁrming  the  existence  of  a  contin-
uum  between  IGE  from  early  to  adulthood  (Panayiotopoulos,
1997).  In  addition,  the  ﬁnding  that  almost  a  quarter  of  our
patients  had  a  ﬁrst-degree  relative  affected  by  IGE  would
conﬁrm  that  the  important  role  of  genetic  factors  in  the  eti-
ology  of  absence  epilepsy  (Doose,  1994;  Loiseau  et  al.,  2002;
Panayiotopoulos,  2005).Mutations  in  SLC2A1  are  a  well-know  cause  of  glucose
transporter-1  (GLUT1)  deﬁciency  (OMIM  606777),  a  severe
disorder  that  results  in  acquired  microcephaly,  intractable
epilepsy,  developmental  delay,  and  additional  neurologi-
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al  manifestations  (e.g.,  ataxia  or  movement  disorders)
Klepper,  2011). However,  in  the  last  few  years  several
bservations  have  signiﬁcantly  expanded  this  phenotype  to
nclude  variable  age  at  onset  and  a  wide  spectrum  of  clin-
cal  manifestations,  including  refractory  and  early-onset
bsence  seizures  (Roulet-Perez  et  al.,  2008;  Suls  et  al.,
009;  Slaughter  et  al.,  2009;  Mullen  et  al.,  2010;  Byrne
t  al.,  2011;  Klepper,  2011) and  the  same  authors  have
emonstrated  a  permanent  frontal  hypometabolism  in  such
atients  (Suls  et  al.,  2008). We  failed  to  identify  SLC2A1
utations  in  the  20  screened  patients,  probably  due  to  the
act  that  we  did  not  identify  children  with  additional  neuro-
ogical  ﬁndings  other  than  epilepsy.  Further  studies  should
ssess  the  diagnostic  impact  of  SLC2A1  screening  in  patients
ith  absence  epilepsy  and  other  IGE.  However,  we  could
peculate  that  in  most  cases  these  epilepsies  follow  com-
lex  inheritance  with  multiple  genes  probably  contributing
o  its  aetiology  as  in  most  common  forms  of  IGE  (Gardiner,
005).
In  summary,  we  showed  that-although  rarely-typical
bsences  epilepsy  can  occur  before  3  years  of  age.  The  ear-
ier  onset  of  absences  does  not  necessarily  imply  a  poor
rognosis.  Indeed,  the  strong  similarities  in  the  main  elec-
roclinical  features  and  outcome  between  children  with
arly-onset  absences  and  those  with  CAE  support  the  view
hat  these  conditions  are  a  continuum  within  the  wide  spec-
rum  of  IGE.  These  ﬁndings  also  conﬁrm  the  difﬁculty  to
dentify  evidence-based  instruments  to  devise  a  syndromic
lassiﬁcation  of  epilepsies  useful  for  clinical  practice.
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